Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Stella Sasso

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Advanced Drug Delivery Reviews|July 12, 2017
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challengesKatharina Maisel, Maria Stella Sasso, Lambert Potin, et al.
Science Advances|March 25, 2021
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomasMaria Stella Sasso, Nikolaos Mitrousis, Yue Wang, et al.
Oncoimmunology|February 14, 2022
T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG miceOlmo Sonzogni, Daniel E Zak, Maria Stella Sasso, et al.
Biomaterials|May 3, 2016
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapyMaria Stella Sasso, Giovanna Lollo, Marion Pitorre, et al.
Journal of Immunotherapy and Precision Oncology|December 8, 2025
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV AdministrationLee S Rosen, Christian Ottensmeier, Maria Hawkins, et al.
Science Translational Medicine|March 21, 2014
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patientsBernhard Mlecnik, Gabriela Bindea, Helen K Angell, et al.
Cancer Cell|September 14, 2016
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic CellsIlaria Marigo, Serena Zilio, Giacomo Desantis, et al.
Biomaterials|October 11, 2021
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvantLaura T Gray, Michal M Raczy, Priscilla S Briquez, et al.
Biorxiv : the Preprint Server for Biology|April 14, 2021
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
ACS Central Science|September 1, 2021
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular ImmunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Advanced Drug Delivery Reviews|July 12, 2017
Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challengesKatharina Maisel, Maria Stella Sasso, Lambert Potin, et al.
Science Advances|March 25, 2021
Lymphangiogenesis-inducing vaccines elicit potent and long-lasting T cell immunity against melanomasMaria Stella Sasso, Nikolaos Mitrousis, Yue Wang, et al.
Oncoimmunology|February 14, 2022
T-SIGn tumor reengineering therapy and CAR T cells synergize in combination therapy to clear human lung tumor xenografts and lung metastases in NSG miceOlmo Sonzogni, Daniel E Zak, Maria Stella Sasso, et al.
Biomaterials|May 3, 2016
Low dose gemcitabine-loaded lipid nanocapsules target monocytic myeloid-derived suppressor cells and potentiate cancer immunotherapyMaria Stella Sasso, Giovanna Lollo, Marion Pitorre, et al.
Journal of Immunotherapy and Precision Oncology|December 8, 2025
Replication-Competent, Tumor-Specific Immuno-Gene Vectors Allow for Exchange of Transgenes and Lead to Viral Persistence Following IV AdministrationLee S Rosen, Christian Ottensmeier, Maria Hawkins, et al.
Science Translational Medicine|March 21, 2014
Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patientsBernhard Mlecnik, Gabriela Bindea, Helen K Angell, et al.
Cancer Cell|September 14, 2016
T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic CellsIlaria Marigo, Serena Zilio, Giacomo Desantis, et al.
Biomaterials|October 11, 2021
Generation of potent cellular and humoral immunity against SARS-CoV-2 antigens via conjugation to a polymeric glyco-adjuvantLaura T Gray, Michal M Raczy, Priscilla S Briquez, et al.
Biorxiv : the Preprint Server for Biology|April 14, 2021
Polymersomes decorated with SARS-CoV-2 spike protein receptor binding domain elicit robust humoral and cellular immunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
ACS Central Science|September 1, 2021
Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular ImmunityLisa R Volpatti, Rachel P Wallace, Shijie Cao, et al.
Pageof 1